A bstract. Monoclonal antibodies directed against human renin were obtained by the fusing of myeloma cells with spleen cells from Balb/c or highresponder Biozzi mice injected with pure tumoral or highly purified renal renin. These procedures resulted in the production of seven stable monoclonal antibodies to human renin. Antibodies in the hybridoma culture medium were screened by binding to pure iodinated renin or insolubilized renin in a solid phase assay. The concentration of purified antibodies that provided a 50% binding to iodinated renin varied from 1 X 10-10 to 1 X 10-7 M. Two monoclonal antibodies were found to be potent inhibitors of renin enzymatic activity in vitro, behaving as noncompetitive inhibitors (Ki, 1 to 4 X 10`s M). They were specific for primate renin. Three monoclonal antibodies provided suitable immunoadsorbants for renin purification. One of these immunoadsorbants was used for large-scale purification of the renal enzyme, resulting in an 825-fold renin enrichment in a single step. Two antibodies were able to distinguish between active and inactive renin and enabled concomitant separation and purification of the two enzyme forms in various biological fluids. Monoclonal antibodies also stained human and monkey renal renin when indirect immunofluorescence and peroxidase-antiperoxidase techniques were used. A highly sensitive radioimDr. Atlas is with the
Introduction
Renin (EC 3-4-99-19), a key enzyme in the regulation of blood pressure and sodium and potassium metabolism, is present in human kidney and biological fluids in minute quantities. Its purification from a juxtaglomerular cell tumor (1) and from cadaver kidney (2, 3) facilitated the characterization of the enzyme and the generation of polyclonal antibodies in the rabbit. Polyclonal antibodies against human renin were used to set up a direct radioimmunoassay (RIA)' (4), to localize renin by immunohistochemistry (5, 6) , and to block in vivo the renin enzymatic activity in an experimental model of hypertension in the monkey (7, 8) . There are, however, several limitations in the use of antirenin polyclonal antibodies: The scarcity of pure human renin means that the supply of antisera is limited and that the purification of antibodies on a renin affinity column is not feasible. These antibodies cannot distinguish between active and inactive plasma renin (9, 10) . Inactive renin can be fully activated by limited proteolysis, acidification, or cold exposure (see review, 1 1) . The exact nature of inactive renin has not been elucidated, but the availability of antibodies that could distinguish between these two forms would be extremely valuable.
For these reasons, monoclonal antibodies directed against human renin were sought. The preparation of such a mono-clonal antibody, F15, has recently been reported (12) . This antibody had a low affinity for renin, poorly inhibited renin enzymatic activity, could not distinguish between active and inactive renin, and could not be used for renin immunohistochemistry; however, it enabled effective purification of renin by immunoaffinity. This paper describes the search for a set of monoclonal antibodies against human renin that would overcome the limitations of the currently available polyclonal and monoclonal antibodies.
The strategy used was to purify human kidney renin by immunoaffinity on a column of F15-Sepharose gel. This purified renin, along with pure renin obtained in this laboratory (1) , was injected into mice, and a set of monoclonal antibodies was obtained by lymphocyte hybridization. The following properties and applications of monoclonal antibodies were studied: their affinity, their specificity with regard to renin from different species and acid proteases, their ability to inhibit renin enzymatic activity, their usefulness in immunoaffinity chromatography, their ability to distinguish between active and inactive renin, their use for renin localization by immunohistochemistry, and the establishment of a new radioimmunometric assay of renin in human plasma. This study shows that monoclonal antibodies with different properties can be obtained and used for various investigations in the renin-angiotensin system.
Methods
Human renin and polyclonal antibody sources I. INTERNATIONAL STANDARD RENIN. This kidney renin was donated by the Medical Research Council (MRC) (Holly Hill, London; lot 68/356).
II. CRUDE RENAL RENIN. Infarcted kidney removed at surgery was homogenized in 0.1 M phosphate buffer, pH 7.5, which contained protease inhibitors (4 ml/g tissue) as described (13) . After 30 min of centrifugation at 20,000 g the supernatant was removed and stored at -20'C. The specific activity was 0.5 Goldblatt units (GU)/mg protein.
III. HAAS RENIN. This renin was partially purified from cadaver kidney (step V) (14) and was generously donated by Dr. Haas, Mount Sinai Hospital (Cleveland, OH). The specific activity of the lyophilized preparation was 0. 132 GU/mg protein.
IV. PURE RENIN. Pure renin was obtained from a juxtaglomerular cell tumor (1) . The specific activity was 810 GU/mg protein. This preparation was used for the iodination of renin as described (4) .
V. INACTIVE RENAL RENIN. Inactive renin was extracted from
480 g of human cadaver kidney cortex and was purified 290-fold (specific activity, 0.29 GU/mg protein, 52% recovery) on cibacron blue F3GA agarose (Bio-Rad Laboratories, Richmond, CA), phenylSepharose, and DEAE-Sepharose, as previously described (15 VII. RENIN FROM AMNIOTIC LIQUID. Amniotic fluid was collected by amniocentesis during the third trimester of pregnancy. Amniotic liquid was centrifuged and stored at -20'C. It contained 1.09 mGU/ml of active renin and 9.4 mGU/ml of inactive renin.
VIII. PLASMA RENIN. 10 ml blood was collected at 4VC on 100 IU dry heparin (Choay Lab., Paris), centrifuged, and stored at -20'C. Plasma was obtained from normal volunteers. For the separation of active and inactive renin on the 4GI-Sepharose column, plasma from a hypertensive patient with high renin activity was used (plasma renin activity (PRA), 39.6 ng angiotensin I/ml per h).
IX. POLYCLONAL ANTIBODIES. Anti-human renin antibodies (referred to as RI 5) (4) inhibit renin enzymatic activity and stain renin in the human kidney (5).
Production of renin monoclonal antibodies IMMUNIZATION. Balb/c or high-responder Biozzi mice (17) were injected with pure human renin purified from a juxtaglomerular cell tumor that had a specific activity of 810 GU/mg protein (1) (4) . Iodinated renin was stable for 6 wks. Nonspecific binding was measured for each experiment and averaged 9%. The titer of the antibody was defined as the dilution of the hybridoma culture medium that provided 50% of the maximum binding of tracer. For the solidphase assay, a 2-jg/ml solution of pure renin was adsorbed to the wells of a polyvinyl microplate overnight at 40C. The plates were washed, and supernatants of the hybridoma cultures were incubated in the renin-coated wells for 3 h at room temperature. lodinated goatanti-mouse IgG (Tago Biosoft, Paris) was then added and incubated for 3 h at the same temperature. After extensive washings the wells were cut out and counted in a gamma scintillation counter.
HYBRIDOMA CLONING. Antibody-producing hybridomas were cloned and subcloned with a cloning cell sorter (FACS IV; BectonDickinson and Co., Becton-Dickinson FACS, Paramus, NJ).
MASS PRODUCTION OF MONOCLONAL ANTIBODIES. Ascites were produced after intraperitoneal injection of cloned hybridoma cells into pristane-treated Balb/c mice. Monoclonal antibodies were then purified from ascites by affinity chromatography on protein ASepharose (20) , with an 85% recovery. The purity of the antibodies was assessed by both immunoelectrophoresis and isoelectrofocusing to be >95%. Isotypes were determined by immunoelectrophoresis with anti-subclass mice antibodies (Miles Laboratories, Inc., Elkhart, IN). KINETIC PROPERTIES OF MONOCLONAL ANTIBODIES. Scatchard determination. The association constant for the antibodies with human renin was determined by use of the supernatant of the culture media according to Scatchard (22) . The concentrations of pure tumoral renin varied from 2 X 108 to 1.5 X 10-'0 M. Pure iodinated human renin was used as the tracer. Separation of bound and free renin was performed with polyethylene-glycol (4).
Kinetics of renin inhibition. The kinetics of the inhibition of renin by 4GI-and 4BII-purified monoclonal antibodies were studied. 25 M(GU of MRC human renin was incubated at 370, pH 7.4, with three different concentrations of a renin-free angiotensinogen prepared from human plasma as described (10) SPECIFICITY OF MONOCLONAL ANTIBODIES. Direct RIA. This assay was performed to evaluate the capacity of monoclonal antibodies raised against human renin to bind renin of other species or to bind other acid proteases. The RIA of human renin was performed as described (4) by use of the supernatants of hybridoma culture 4GI and 4B 11 as antibodies. Standard curves were obtained with pure human renin (1 to 100 ng). In the same assay were run purified human renal inactive renin (I to 100 ng; see above, renin source V); pure mouse submaxillary gland renin (24) (10-10,000 ng); pure hog renin (25) (10- Enzymatic assay. In this assay we determined the ability of 4(1 and 4BI I monoclonal antibodies to inhibit the enzymatic activity of renin in various species. The PRA was determined at pH 7.4 in man, dog, hog, rabbit, mouse, rat, and monkey (Marmoset and Papio). Results are expressed as the percentage of angiotensin I generated per hour as compared with the level of angiotensin I generated in the absence of antibody.
Applications of monoclonal antibodies ANALYTICAL AFFINITY CHROMATOGRAPHY. The purified IgG fractions of four separate monoclonal antibodies, F15, IA15, 2D12, and 4GI, were coupled to Sepharose 4B as described (27). 2 mg IgG were coupled per milliliter of moist gel. 88% of the IgG was effectively coupled to the gel. The immunoadsorbants were washed with I M NaCI, 0.1 M citrate-phosphate buffer, pH 4.5, 6 M urea, and water, and equilibrated in 0.1 M phosphate buffer, pH 7.5 0.5 ml of each of the four gels was packed in Pasteur pipettes and tested for the ability to bind human renin. The renin preparation applied to the gels consisted of 3 to 5 GU crude renal renin supplemented with -50,000 cpm iodinated renin (compare renin source II). The columns were eluted with the following agents: 0.1 M phosphate buffer, pH 7.5; 0.1 M citrate-phosphate buffer, pH 4.5; 0.1 M citrate-phosphate buffer, pH 4.5, containing 2 M NaCI, followed by the same buffer containing I to 6 M urea. The radioactivity of each eluant was counted and the renin concentration was measured by direct RIA (4) .
The 4GI-gel was also tested for its ability to separate active from inactive renin. Different sources of inactive renin were used: (a) the culture medium of chorionic cells, 5 ml of which was applied to 0.5 ml of gel at pH 7.5. The gel was eluted with citrate-phosphate buffer, pH 4.5, then with 6 M urea. Renin was measured in the fractions by direct RIA. Also used were (b) renal inactive renin; and (c) amniotic liquid (2 ml) and plasma (5 ml), which contain both active and inactive renin. In these experiments renin was measured in the fractions by the enzymatic assay before and after trypsin activation as described (28) .
PURIFICATION OF HUMAN RENIN. The purified IgG fraction of F15 was coupled to cyanogen bromide-activated Sepharose 4B (27) by use of 10 mg IgG/ml of moist gel. Haas renin (1,780 GU) was used as starting material. The renin sample was dialyzed twice against 25 vol of 0.1 M phosphate buffer, pH 7.5, and applied by gravity to a I X 13 cm column of gel equilibrated with the same buffer. The column was washed extensively with the starting buffer (10 bed vol), and renin was then eluted with 0.1 M citrate-phosphate buffer, pH 4;0, containing 2.0 M NaCl, at a flow rate of 0.3 ml/min. After absorbance was measured at 280 nm, each fraction was adjusted to pH 5.0 with 0.7 M Na3PO4, and three protease inhibitors were added at a final concentration of 3 mM (benzamidine-HCl, Na2-EDTA, and sodium tetrathionate). The renin-containing fractions were pooled and concentrated by the use of a PM-10 membrane (Amicon Corp., Scientific Systems Div., Danvers, MA).
Renin was measured both by its enzymatic activity and by direct RIA. For the enzymatic activity, samples were diluted to a final renin concentration of -2 X 10-5 GU/ml. The assays were standardized with the MRC renin standard and the results were expressed as Goldblatt units per milliliter. The direct RIA was performed with pure human renin (25 to 800 pg/tube) as the standard. Samples were diluted in RIA buffer (0.1 M phosphate buffer, pH 7.5, containing I mg/ml BSA). In addition, a modified RIA, the rapid RIA, was used to screen chromatographic fractions. The equilibration time was reduced to 2 h at 20'C by decreasing the sensitivity (standard curve, 0.43 to 6.9 ng renin/tube) and increasing the concentration of antiserum. The results of both methods (i.e., the sensitive and the rapid RIA) are expressed as Goldblatt units per milliliter, based on a specific activity for pure renin of 810 GU/mg protein. Protein was measured by a slight modification of the method of Lowry et al. (29) , with crystalline BSA (Sigma Chemical Co.) as standard. To maximize the sensitivity of the method, the total reaction volume was reduced to 1.2 ml, permitting samples of up to 100 Ml, and absorbance was measured at 750 nm.
The standard curve was linear between 1 and 15 Mg BSA.
IMMUNOFLUORESCENCE AND IMMUNOPEROXIDASE. Human and monkey renal cortex were fixed in Bouin's solution and embedded in paraffin. After they were washed in phosphate buffered saline (PBS)-BSA, the slices were incubated with IA12 or 2D12 purified monoclonal antibodies. After a washing with PBS-BSA, the preparations were incubated with goat IgG-fluorescein isothiocyanate conjugated antimouse IgG (Miles Laboratories, Inc.). Counter staining was with 0.01% Evans blue. The peroxidase-antiperoxidase (PAP) technique was that of Sternberger (30) . The first incubation was with IA12 or 2D12 purified antibodies and the second was with goat IgG anti-mouse IgG (Miles Laboratories, Inc.); the third incubation was with mouse-PAP (Miles Laboratories, Inc.). Diaminobenzidine H202 was used as a chromogenic substrate for the peroxidase. The nuclei were stained with hematoxylin.
The negative control was the replacement of the monoclonal renin antibodies (IA12 or 2D12) by the anti-dinitrophenol monoclonal antibody. The positive control was the use of polyclonal renin antibodies (Rl 5) instead of the monoclonal antibodies.
RADIOIMMUNOMETRIC ASSAY OF RENIN. The radioimmunometric assay measured renin in a sandwich between two monoclonal renin antibodies. The first unlabeled monoclonal antibody was coated on the plates and the second one was iodinated.
Monoclonal antibodies were iodinated by use of the chloramine T method (31) . Iodinated antibodies were further purified on Sephacryl S 300. The labeled antibodies had a specific activity of 15 MCi/Mtg.
The assays were performed on polyvinyl microtitration plates (Falcon Labware, Div. Becton-Dickinson and Co., Oxnard, CA). The plates were coated with the first monoclonal antibody (50 Mg/ml), incubated for 18 h at 4°C, washed several times, and then incubated with 150 Ml of renin samples or human plasma for 24 h at 4°C. 200,000 cpm of the second monoclonal antibody were added and incubated for 24 h at 4°C. The wells were then cut and counted in a gamma scintillation counter.
Twenty-four distinct pairs of monoclonal antibodies were tested to select the pair that provided the higher sensitivity in renin assay. The F15 antibody was not tested in the immunometric screening, owing to its low affinity for renin.
Results

Fusions
As shown in Table I , the quantity, the source, and the manner of administration of human renin changed from one fusion to another. The first three fusions were performed with spleen cells from Balb/c mice injected with pure tumoral renin. This protocol resulted in the production of only one stable monoclonal antibody, F1 5. The last two fusions were performed with the spleen cells from high-responder Biozzi mice. In the case of the F37 fusion, the mouse was first injected with tumoral renin and boostered with renal renin. The Biozzi mouse used for the F55 fusion was injected exclusively with renal renin. Both Biozzi mice had high levels of circulating renin antibodies (compare Table I ). Fusions F37 and F55 resulted in the production of two and four stable monoclonal antibodies, respectively. human renal and plasma renin was studied. There was no inhibition with antibodies lA12, 2D12, 3E8, and 4E1. However F15, 4B1 1, and 4G1 inhibited renin activity. Fig. 3 shows the inhibition of PRA with various dilutions of the hybridoma supernatants. F15 inhibited weakly whereas 4Bl1 and 4G1 were potent inhibitors; 50% inhibition was obtained at 1/100-and 1/600-fold dilutions for 4G1 and 4B1 1, respectively.
The kinetics of renin inhibition by pure 4G1 and 4B1 1 are given in Fig. 4 . The different representations show that both antibodies act as noncompetitive inhibitors of renin Antibody dilution Figure 3 . Inhibition of renin enzymatic activity. On the abscissa, the dilution of hybridoma supernatants and of antiserum is represented by ., 4G1; o, F15; *, 4B1 1; and ,, R15. Specificity for renin. Fig. 5 shows the standard curves for a human renin RIAs performed with 4G1 and 4B 11. 0.1 nM active renin was detected when 4B 11 was used, as compared with 0.5 nM when 4G1 was used. In contrast, neither 50 nM hog renin nor 500 nM mouse renin bound to these two antibodies, nor was there any binding of 500 nM of the acid proteases pepsin and cathepsin D to any of the antibodies.
The specificity of 4G1 and 4B11 antibodies for human renin was further confirmed by the low percentage of PRA inhibition by the antibodies in the dog, hog, rabbit, mouse, and rat (Table II) . However, both antibodies inhibited monkey renin in Papio and Marmoset strains.
Behavior of active and inactive renin on immunoaffinity nM protein Figure 5 . Determination of the specificity of 4BI I and 4GI antibodies. RIA of human renin using 4BI I and 4GI as antibodies. *, pure human tumoral renin; o, inactive renin purified from human kidney; *, hog renin; *, mouse submaxillary gland renin; A, human cathepsin D; and a, hog pepsin. B/Bo, bound/unbound. gels. Fig. 6 summarizes the behavior of active renin on the four immunoadsorbants. The 2D112 gel did not retain renin, but the other three gels bound both iodinated and crude renal renin. However, up to 18% of iodinated renin was not retained at pH 7.5. Renin adsorbed on lA12-and F15-gels was easily eluted at pH 4.5 in the presence of 2 M NaCl, whereas the enzyme was not removed from the 4G 1-gel under these conditions. In separate experiments conducted at neutral pH, elution was obtained with 1 M urea for the F15-gel, but 6 M urea was required to elute renin from the 4G1 and 1A12-gels.
The recovery of active renin in the dialyzed urea fraction averaged 80%.
Inactive renin from chorionic cell culture was also fixed on 4Gl-gel, as shown in Fig. 7 A and was easily eluted when the pH was decreased to 4.5. A similar pattern was obtained for the elution of renal inactive renin (Fig. 7 D) . Active renin was much more strongly retained on the same gel, requiring 6 M urea for elution (compare Fig. 6 ). 728 Galen et al. Renins from amniotic fluid (Fig. 7 B) and plasma ( Fig. 7  C) were also retained on the 4G1-gel. In both cases the renin eluted at pH 4.5 was highly activatable by trypsin treatment ELUTION VOLUME (ml) Figure 6 . Immunopurification of active renin with monoclonal antibodies. 4G1, lA12, 2D12, and F15 antibodies were coupled to Sepharose 4B. 0.5-ml gel columns were equilibrated at pH 7.5 and used to purify human renin (3.0-5.0 GU active renin containing iodinated renin). Eluting agents were (A) 0. (8-fold and 13-fold increase, respectively, for amniotic fluid and plasma). By contrast, active renin eluted in the urea fraction could not be activated by trypsin treatment. The recovery of renin in the purified fractions varied from 80 to 86%. It was not possible to calculate the purification factor because albumin was used in the elution buffer as a carrier. Purification of human renin. In pilot experiments, the capacity of the F15-gel for Haas step V renin was estimated to be 150 GU/ml gel. Accordingly, the crude material available for purification was fractionated and the maximum quantity was applied to the gel each time to avoid dilution of eluted renin. 1,780 GU was applied to a 10-ml gel. Most of the protein appeared in the breakthrough fractions, whereas renin eluted with pH 4.0 buffer (Fig. 8) . By the pooling of the fractions with the highest specific activity, a preparation was obtained with a specific activity of 109 GU/mg, representing a 825-fold enrichment with a yield of 53%. In another preparation 2,200 GU Haas renin was applied to the affinity gel. The renin obtained had a specific activity of 81 GU/mg protein, corresponding to a 787-fold purification. This material was used for the immunization of mice in fusion F37 and F55 and was stable at -80'C for more than 1 yr.
1T
Immunohistochemical localization of renin. The 2D112 antibody (170 gg/ml) stained renin in the macaque kidney by the indirect immunofluorescence method. Fluorescence was observed in the epithelioid cells of the afferent artery (Fig. 9 A). By the same technique the 2D1 2 antibody (170 gg/ml) detected renin in human kidney. Fluorescence was observed in arteriolar cells close to the macula densa (Fig. 9 B) . With the PAP technique the lA12 antibody (750 jg/ml) stained renin in the human kidney, and clusters of renin cytoplasmic granulation were found in the cells of afferent arterioles (Fig.  9 C) . No fluorescence was obtained in macaque and human kidney when monoclonal antibodies to human renin were replaced by an anti-dinitrophenol monoclonal antibody. Table III summarizes the properties and applications of the seven monoclonal antibodies in comparison with those previously reported for the polyclonal antibody R 15 (5, 32, 33) .
Radioimmunometric assay of renin. In a first series of experiments, the binding of renin by various pairs of antibodies was screened at a high concentration of renin (34 ng/well), as shown in Table IV . 13 pairs of antibodies bound renin, another pair bound only slightly. As expected, when the second antibody tested was the same as the first one, no signal was obtained. This accounted for 4 of the 10 negative pairs. In a second series of experiments the 13 positive pairs were tested for their ability to detect decreasing amounts of renin (down to 6.25 pg/well). The two most efficient pairs were 4B1 -4G1 and 3E8-4G 1. Fig. 10 represents the standard curve for a renin assay that used the 3E8-4G1 pair of monoclonal antibodies.
Standard curves were constructed with pure human renin in buffer and renin free plasma (10) . A linear curve was obtained for renin concentrations between 0 and 240 pg/well (Fig. 10 ELUTION VOLUME (ml) Figure 8 . Purification of Haas step V renin on FS5-sepharose. Renin was measured in the fractions by the enzymatic activity assay. The horizontal bracket indicates the fractions that were pooled and concentrated. of plasma paralleled the standard curve built in renin free plasma. Similar results were obtained when the 4BI 1-4G1 pair of antibodies was used (data not shown).
Discussion
Five fusions gave only seven stable monoclonal antibodies against human renin. This may indicate the low antigenicity of human renin. It is difficult to compare the efficiency of the different fusions because the protocols differed: the first fusion was performed on the spleen cells of a Balb/c mouse injected with only 6.2 Ag pure tumoral renin whereas the last fusion was performed with the cells of a Biozzi mouse injected with 115 ug of renal renin 10 times less pure. Nevertheless, results obtained with the Biozzi mice seem better, as six monoclonal antibodies were obtained with two fusions vs. only one with three fusions of Balb/c spleen cells. Similar differences were found for anti-human chorionic gonadotropin monoclonal antibodies (34) .
Six of our seven antibodies were mass produced in ascitic fluid. However, the production of 4B1 1 in ascites gave low concentrations of antibodies, requiring an in vitro method of production to be set up.
Antibodies were screened by their capacity to bind pure iodinated renin. This test was chosen because of the availability of pure renin and because of its simplicity and reproducibility. Original magnification X 160. B, human kidney stained by the indirect fluorescence technique using the 2D12 antibody. Renin fluorescence (arrow) was found in the arteriolar cell close to the macula densa. Original magnification X 250. C, human kidney stained by the PAP procedure using the IA12 antibody. Clusters of renin cytoplasmic granulations (arrow) were observed into the cells of the afferent arteriole. Original magnification X 320.
It allowed the detection of six of seven antibodies in the hybridoma culture medium. In the present study the antibody titer paralleled the association constant. However, the use of iodinated renin for the screening and studying of renin monoclonal antibodies had its limitations. Three of seven antibodies inhibited the enzymatic activity of renal and plasma renin. This proportion appears high for, as monoclonal antibodies are directed against a unique antigenic site, there is a low probability that this site would involve the active site of the enzyme. For example, I of 5 antibodies inhibited the enzymatic activity of cyclic GMP-stimulated cyclic nucleotide phosphodiesterase (35) and 3 of 16 antibodies inhibited the activity of DNA polymerase (36) . By contrast, Dzau et al. (37) recently reported that five of their six clones that secreted anti-human renin antibodies were inhibitors of the enzymatic activity.
Two of our antibodies, 4G1 and 4B 1, are powerful inhibitors of renin. Kinetic studies demonstrated that they behaved as tight binding inhibitors (Ki < 10-6 M). The analyses of the kinetics based on the Michaelis-Menten equation are still valid, as the concentration of inhibitor that is free in solution is the same as the total inhibitor concentration; i.e., the total enzyme concentration (Et) divided by Ki was <0.01 as calculated by Henderson et al. (38) . In our experiments, Et, total renin concentration, was 1 X 10-12 M and Ki was >1 X 10-0 M. Therefore, Et/Ki was <0.01. The results obtained with the representations of Lineweaver-Burk, Dixon, and Webb were all consistent for a noncompetitive inhibition for both 4B11 (Ki = 3 X 10'0 M) and 4G1 (Ki = 1 X 10-0 M). So it seems that both of these antibodies, when bound, either hinder the access of the active site or alter its catalytic mechanism. They are not directed against the active site itself. (7) and marmoset monkeys (8) . Preliminary results show that the 4G1 antibody was also able to decrease the blood pressure of conscious salt-depleted marmosets (unpublished data).
Another goal of this study was to obtain monoclonal antibodies that allow the immunopurification of renin. Antibodies F15, IA12, and 4G1 coupled to Sepharose bound active renal renin. The conditions of renin elution depended on-the affinity of the antibodies for the active renin molecule.
Renin was easily eluted under mild conditions from the low affinity gel, F15, whereas renin elution from high affinity gels lA 12 and 4G1 required the use of 6 M urea. The availability of a set of monoclonal antibodies that have a large range of affinities is very advantageous compared with polyclonal antibodies. R15 renin antiserum was a poor tool in purifying renin by immunoaffinity, as the elution conditions required were too drastic and the recovery was very low (<20%). It was used only to prepare renin-free plasma as a source of human angiotensinogen (10) . Other authors, using an anti-human renin IgG-Sepharose for immunopurification, obtained a 25% recovery of renin (42) . However, monoclonal antibodies as immunoaffinity ligands provided two interesting applications: one, a large-scale purification of human renin providing in one step an 825-fold renin enrichment from a semipurified material with a 53% recovery; and two, the separation of active from inactive renin. The separation of active from inactive renin was possible because 4B1 1 and 4G1 antibodies recognized inactive renin to a lesser extent than they did active renin.
Indeed, a 4G 1-gel can purify and separate both forms of renin in a single step. This is the case for renin from amniotic liquid, kidney, plasma, and chorionic cell culture. Whatever the renin source, a clear-cut separation is obtained and the inactive renin is retained to a lesser extent on the gel than is active renin. In contrast, polyclonal antibodies (9, 10, 42) and the monoclonal antibody F15 (40) recognize equally both forms of renin.
The separation of inactive and active renin by the 4Gi-gel has important practical applications. Currently, there is no simple method for the simultaneous separation and purification of the two forms of renin. At present the most often used methods of separation of active and inactive renin are affinity chromatography on Sepharose-pepstatin and Affi-ge! blue chromatography. These selectively adsorb one form of renin while the other elutes with the bulk of the proteins (43, 44) . In plasma, inactive renin is difficult to measure without previous purification. The 4Gl-gel will allow a simple and rapid extraction of inactive renin from plasma and, hence, the development of an assay for the inactive enzyme.
Renin was localized in the kidney by immunohistochemistry with monoclonal antibodies, as it was with polyclonal antibodies. This result is important for it means that from now on immunohistochemical studies of renin can be carried out with an unlimited source of pure antibodies. The radioimmunometric assay offers several advantages over the existing direct RIA for renin, which we described for polyclonal antibodies (10) : a linear standard curve that allows the detection of renin between 3 and 240 pg; no requirement for pure iodinated renin; and enhanced sensitivity (3 pg The immunometric assay is sensitive enough to detect renin in normal subjects, and the evaluation of this new radioimmunometric assay of renin is in progress to discover whether plasma renin can be detected under any physiopathological circumstances and to determine which form(s) of renin is being measured.
In conclusion, one has to ask if monoclonal antibodies are more useful than their polyclonal counterparts. Monoclonal antibodies take longer and cost more to produce. However, the availability of antibodies in a pure form and unlimited scale are ample justification for such an enterprise. The results obtained in immunohistochemistry for the localization of renin are similar with both polyclonal and monoclonal antibodies. Both monoclonal and polyclonal antibodies are expected to evoke the same decrease in blood pressure in salt-depleted monkeys. Properties that are unique to monoclonal antibodies and that are of biological interest are the separation of active and inactive renin from different sources, the qualitative and quantitative purification of the enzyme, and a more sensitive direct assay of human plasma renin. This set of monoclonal antibodies has proved therefore to be a highly valuable new tool in the investigation of the renin-angiotensin system.
